FOLLOW UP CASES OF BEDAQUILINE IN XDR-TB PATIENTS: NOVEL CASE SERIES

Tuberculosis (TB) is one of the top 10 causes of death and the leading cause from a single infectious agent. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Aglobal total of 2,06,030 people with multidrug or Rifampicin-resistant TB (MDR/RRTB) were detected and notied in 2019. Bedaquiline to be used to treat drug resistant TB.The drug is available as part of second line treatment for patients suffering from MDR-TB and XDR-TB. The drug recently underwent clinical trials at the national level in certain hospitals for safety and efcacy.Because XDR TB is resistant to the most potent TB drugs, the remaining treatment options are less effective, have more side effects, and are more expensive3.